News | July 10, 2008

Micrus Endovascular Receives Approval to Market Cerecyte Microcoils in Japan

July 11, 2008 - Micrus Endovascular Corp. said this week it received approval from the Ministry of Health, Labour and Welfare (MHLW) to market in Japan the Cerecyte microcoil product line, including the MicruSphere, Presidio, HeliPaq and UltiPaq Cerecyte embolic coils, for the endovascular treatment of cerebral aneurysms.

Sales of the company’s Cerecyte microcoils will be managed by Goodman Co., Ltd., Micrus Endovascular’s exclusive distributor in the Japanese market.

Micrus develops, manufactures and markets implantable and disposable medical devices for use in the treatment of cerebral vascular diseases. Micrus products are used by interventional neuroradiologists, interventional neurologists and neurosurgeons to treat both cerebral aneurysms responsible for hemorrhagic stroke and intracranial atherosclerosis, which may lead to ischemic stroke.

For more information: www.micruscorp.com


Additional Content

News | Embolization devices

Aug. 20, 2026 – The novel, radiopaque, polymer-based embolic coil from Embolization, Inc. has now surpassed 125 implants ...

Home August 20, 2026
Home
News | Embolization devices

June 8, 2026 – Embolization, Inc. will present its novel embolization coil, using proprietary shape-memory biocompatible ...

Home June 08, 2026
Home
News | Embolization devices

June 5, 2025 – Penumbra, Inc. has announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby ...

Home June 05, 2025
Home
News | Embolization devices

July 28, 2022 — Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral ...

Home July 28, 2022
Home
News | Embolization devices
March 31, 2022 – Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral ...
Home March 31, 2022
Home
Subscribe Now